The pain management pharmaceuticals market in the U.S. is being driven by the continued development of selective cyclooxygenase-2 (COX-2) inhibitors, triptans, and extended-release formulations of opioid drugs, according to new analysis by the consulting firm of Frost & Sullivan. In 1997, the company released a similar report. In the intervening six years, the market has undergone dramatic changes.
Targeted Drug Combination Reveals New Activity in Brain Tumors
December 28th 2021A combination of two targeted cancer drugs showed unprecedented, “clinically meaningful” activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.
2 Clarke Drive
Cranbury, NJ 08512